A Phase 3 interventional study of Avelox (Moxifloxacin, BAY12-8039) and Amoxicilline/clavulanic in Infectious Diseases, sponsored by Bayer. Completed at 22 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-12-08.
Sponsored by Bayer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Communicable Diseases with a site in Italy — 9 open to participants now, 10 under way, none of them phase 3. Communicable Diseases · Italy.
Among the 21 studies in Communicable Diseases with a site in Italy, this one is the only one that started in 2008, is the only one in phase 3, and was the 1st registered.
627 studies on the registry are indexed under Communicable Diseases; 128 are open to participants now.
Browse Communicable Diseases studies →9 of the 21 studies in Communicable Diseases with a site in Italy are open now. Recruiting first, the newest first:
AusperBio Therapeutics Inc. · Sites in Italy, United States, Canada and 3 more countries
Ages 18–65
Azienda Ospedaliero-Universitaria Careggi · Sites in Italy
Ages 18–90
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Sites in Italy
Ages 18+
University Magna Graecia · Sites in Italy
Ages 18+
European Clinical Research Alliance for Infectious Diseases (ECRAID) · Sites in Italy, Belgium, Croatia and 7 more countries
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 91 Communicable Diseases studies recruiting now, 49 (54%) set no upper age limit and 32 (35%) stop at 75 or younger; 35 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 1 started in 2008.
This study's enrollment of 16 is below the median of 89 across 380 interventional studies indexed under Communicable Diseases.
Median enrollment 60 across the 7 interventional studies, 140 across the 14 observational. Of the 6 that completed or were terminated, 1 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 21 have an industry lead sponsor. The 10 most frequent:
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
Bayer has 2 studies filed under Communicable Diseases — fewer than ten, so there is no comparison to draw.
3 of the studies in Communicable Diseases with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05814237European Clinical Research Alliance for Infectious Diseases (ECRAID)POS-ARI-ER Observational Study of Acute Respiratory Infections | 2027-02-28 |
| NCT07654283AusperBio Therapeutics Inc.Study of AHB-137 in Chronic Hepatitis B (CHB) Participants in North America and Europe Regions | 2027-05-11 |
| NCT07429864Fondazione Policlinico Universitario Agostino Gemelli IRCCSChanges in Bile Acids and Microbiota in Patients With Hepatitis D Treated With Bulvertide | 2027-10 |
Add all 3 to your calendar (.ics) → With an account.
Among the 21 studies in Communicable Diseases with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess if a therapy with intravenous and oral moxifloxacin is as effective as a therapy with intravenous and oral amoxicilline/clavulanate in the treatment of complicated skin and skin structure infection.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Men or women of age >/= 18 years with a diagnosis of bacterial skin and skin structure infection that requires
Complicated by at least one of the following criteria:
Diagnosis of one of the following skin and skin structure infections:
Presence of at least 3 of the following local signs and symptoms
Exclusion Criteria:
The following skin and skin structure infections:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Avelox (Moxifloxacin, BAY12-8039)
Drug: Amoxicilline/clavulanic
Sequential IV/PO moxifloxacin 400/400 mg every 24 hours, for 7 to 21 days.
IV Amoxicilline/clavulanic acid 2000/200 mg TID followed by PO amoxicilline/clavulanate 875/125 mg TID for a total of 7 to 21 days
Clinical response up to 14-21 days after the completion of study drug therapy (Test-of-Cure visit [TOC]).
Time frame: Test-of-Cure visit [TOC].
Clinical response assessed by the investigator on treatment Day 3-5
Time frame: Day 3-5
Clinical response assessed by the investigator at the end-of-therapy (EOT).
Time frame: At the end-of-therapy (EOT)
Time to switch from oral to IV therapy
Time frame: Day of switch from oral to IV therapy
Bacteriological response (for microbiologically valid population) at the EOT and TOC
Time frame: At the end-of-therapy (EOT), Test-of-Cure visit [TOC].
The record gives a start of Nov 2008, a primary completion of Sep 2009 and a completion of Oct 2009. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Moxifloxacin